Background
- ProMisE criteria classifies four molecular subtypes of endometrial tumors (ET): DNA polymerase epsilon (POLE) mutated, mismatch repair deficient (MMRd), p53 wild type and mutant. There is limited understanding about prognosis when tumors have alterations in multiple classifiers.
- We report the frequency and outcomes of multi-classifier tumors in addition to high-grade biomarkers (loss of heterozygosity [LOH] and cyclin E1 amplification [CCNE1-amp]).